Key Takeaways
Confused about treatment options?
Get a free second opinion from our oncologists
Germany doesn’t just treat prostate cancer well. It treats it better than almost anywhere else on earth – and the data backs that up.
The 5-year relative survival rate for prostate cancer in Germany is 92%, according to the German Cancer Registry (Krebsdaten.de). That’s not luck. It’s the result of decades of investment in specialist infrastructure, surgical volume, and access to therapies that most countries simply don’t have.
Here’s what sets Germany apart:
For patients from the USA, UK, or Gulf countries, the combination of clinical excellence, lower cost, and access to therapies not available at home makes Germany the destination worth serious consideration.
Germany offers both the standard treatments you’d expect at any major cancer centre and cutting-edge options that remain unavailable or extremely limited elsewhere. Every treatment plan is built individually – your Gleason score, PSA level, stage, age, and personal priorities all shape the recommendation.
Robotic-assisted radical prostatectomy using the da Vinci system is the gold standard for localised prostate cancer in Germany. The surgeon controls robotic arms with 7 degrees of freedom, viewing a magnified 3D image of the surgical field – which allows precise identification of nerve bundles and blood vessels that must be preserved.
The advantages over open surgery are real: less blood loss, shorter hospital stay (typically 5–7 days), and significantly better outcomes for urinary continence and erectile function preservation. German centres have been performing this procedure since 2004, giving them two decades of accumulated expertise.
Cost range: €18,000–€20,000 (vs. $30,000–$50,000 in the USA)
For patients who prefer to avoid surgery – or who have contraindications – radiation is a highly effective alternative for localised and locally advanced disease.
German centres offer:
German hospitals also use rectal spacers to protect healthy tissue during prostate radiation – a standard precaution that reduces complication rates.
Cost range: €12,000–€18,000
Proton therapy delivers radiation with extraordinary precision. Unlike conventional X-ray radiation, protons deposit most of their energy at a specific depth (the Bragg peak), then stop – meaning the tissue beyond the tumour receives virtually no dose.
For prostate cancer, this translates into lower rates of bowel and bladder side effects compared to standard radiation. Germany has multiple dedicated proton therapy centres, including at Charité Berlin and the Rinecker Proton Therapy Center in Munich.
Cost range: €20,000–€35,000
HIFU is a non-invasive, outpatient procedure that destroys prostate tissue using focused ultrasound waves – no incisions, no radiation. It’s particularly well-suited to localised prostate cancer in patients who want to avoid surgery and its associated recovery.
The procedure takes 2–3 hours under general or spinal anaesthesia. Most patients go home the same day or after one night. HIFU can also be used to treat local recurrence after initial treatment.
Cost range: €8,000–€15,000
NanoKnife is one of the most advanced focal therapies available for prostate cancer – and Germany is home to some of the world’s most experienced practitioners, including Prof. Dr. Michael K. Stehling, who has treated over 1,500 patients with this technique.
The procedure uses short electrical pulses delivered through 2–6 thin probes to create nanopores in cancer cell membranes, causing selective cell death. Critically, it does not damage nerves, blood vessels, or surrounding healthy tissue – making it ideal for tumours near critical structures.
Key facts:
Ideal candidates have localised prostate cancer (T1c–T2a), PSA under 15 ng/ml, and Gleason score ≤7.
Cost range: €10,000–€18,000
This is the therapy that has genuinely changed the picture for metastatic prostate cancer – and Germany is a global leader in delivering it.
Lutetium-177 PSMA-617 (also known as Pluvicto) was developed through translational research at DKFZ Heidelberg, Heidelberg University, and Heidelberg University Hospital. It works by attaching a radioactive isotope (Lu-177) to a molecule that binds to PSMA – a protein found in large quantities on the surface of prostate cancer cells. Once bound, the radioactive compound irradiates the cancer cell from within, while leaving surrounding tissue largely unaffected.
In the pivotal VISION trial, Lu-177 PSMA-617 reduced overall mortality by 38% and cut the risk of disease progression or death by 60% compared to standard care alone. PSA declines were observed in approximately 70% of treated patients.
The therapy is delivered in nuclear medicine centres on an inpatient basis, with a stay of 3–5 days per cycle. Most patients receive 3–6 cycles at 6–8 week intervals.
Cost range: €15,000–€25,000 per cycle
Androgen deprivation therapy (ADT) is used across multiple stages of prostate cancer – as a primary treatment for locally advanced disease, in combination with radiation, or as systemic therapy for metastatic disease.
ADT works by suppressing testosterone, which fuels prostate cancer growth. German oncologists use it strategically: combined with radiation for locally advanced disease, or alongside newer hormonal agents (enzalutamide, abiraterone) for castration-resistant cases.
For patients with hormone-resistant metastatic prostate cancer, immunotherapy offers an option when chemotherapy and other treatments are no longer effective.
German centres offer four types:
Dendritic cell therapy involves drawing the patient’s blood, isolating monocytes, transforming them into dendritic cells in a laboratory, and reinfusing them as a personalised cancer vaccine. Side effects are typically mild.
For low-risk, localised prostate cancer – particularly in older patients or those with slow-growing tumours – Germany’s oncologists follow structured active surveillance protocols aligned with the European Association of Urology (EAU) guidelines.
Active surveillance means regular PSA testing, MRI, and repeat biopsy on a defined schedule, with treatment initiated only if the disease progresses. It avoids the side effects of immediate treatment for patients who may never need it.
At this stage, the tumour is confined to the prostate. Cure is the realistic goal. The three main options – radical prostatectomy, radiation therapy, and active surveillance – are all viable, and the choice depends on your Gleason score, PSA level, age, and personal priorities.
German tumour boards will present all three options with their respective risk profiles. For younger, fit patients with intermediate- or high-risk disease, surgery or radiation is typically recommended. For low-risk, slow-growing tumours, active surveillance is increasingly the first choice – consistent with the updated EAU 2024 guidelines.
When the tumour has broken through the prostate capsule (T3) or reached adjacent organs (T4), a combination approach becomes standard. This typically means radiation therapy combined with long-term hormone therapy (ADT) – a combination that significantly improves outcomes compared to either treatment alone.
In selected patients, radical prostatectomy combined with complete androgen blockade remains an option. German centres also use PSMA PET-CT to assess lymph node involvement before finalising the plan.
Metastatic disease requires systemic treatment. Germany’s advantage here is access to the full toolkit:
For many patients from the USA, UK, and Gulf countries, Stage 4 is precisely the scenario where Germany offers something their home system cannot.
Germany has over 50 certified prostate cancer centres. These are the institutions that consistently deliver the highest volume, most advanced care, and best-documented outcomes for international patients.
The Martini-Klinik is the world’s highest-volume prostate cancer centre. Full stop. Located on the grounds of the University Medical Center Hamburg-Eppendorf (UKE), it has treated over 30,000 prostate cancer patients and performs more radical prostatectomies annually than any other institution globally.
That volume matters. Surgical outcomes for continence and potency preservation at Martini-Klinik consistently exceed those reported at lower-volume centres. The clinic is a leader in nerve-sparing robotic prostatectomy and uses MRI-guided fusion biopsy as standard diagnostic practice.
Europe’s largest university hospital, with over 3,000 beds across multiple campuses. Charité’s Comprehensive Cancer Center (CCCC) covers prostate cancer through a dedicated uro-oncology programme with weekly multidisciplinary tumour board reviews. The hospital offers proton therapy, CyberKnife radiosurgery, and participates in numerous international clinical trials. It’s the reference centre for complex and rare presentations.
A leading centre for proton therapy and radiation oncology in Germany. UKM’s urology department is highly experienced in both surgical and radiation management of prostate cancer, with a strong research programme in PSMA-targeted diagnostics and therapy.
Vitus specialises in individualised and focal therapies for prostate cancer – particularly HIFU and NanoKnife (IRE). It’s the clinic of choice for patients seeking non-surgical, nerve-sparing focal treatment for localised disease, and has built a strong international patient programme with dedicated English-speaking coordinators.
Urologie Gronau operates the Prostate Center Europe and has performed over 25,000 robotic prostatectomies since 2006 – making it one of the most experienced robotic surgery centres in the world. The centre runs five da Vinci systems, more than any other clinic in Europe, and has a dedicated international patient coordination office that has been supporting foreign patients since 2006. Patients from the USA, UK, and Gulf countries are routinely treated here.
LMU Munich’s Comprehensive Cancer Center Munich (CCC Munich) is one of Germany’s top-ranked oncology programmes. The urology department, headed by Prof. Dr. Christian G. Stief, is particularly strong in robotic surgery and Lutetium-177 PSMA therapy – LMU’s nuclear medicine department is one of the leading Lu-177 centres in Europe. International patients benefit from a dedicated international office with interpreter services and full travel coordination.
German treatment costs are substantially lower than in the USA – typically 40–60% less for equivalent procedures – while matching or exceeding clinical quality. Pricing is regulated through the G-DRG (Diagnosis-Related Groups) system, which means transparent, predictable costs without the surprise billing that characterises the US system.
| Treatment | Cost in Germany | Cost in USA (comparison) |
|---|---|---|
| Robotic Prostatectomy (da Vinci) | €18,000–€20,000 | $30,000–$50,000 |
| Radiation Therapy (IMRT) | €12,000–€18,000 | $20,000–$40,000 |
| Proton Therapy | €20,000–€35,000 | $40,000–$80,000 |
| Lutetium-177 PSMA Therapy (per cycle) | €15,000–€25,000 | $50,000–$80,000 |
| HIFU | €8,000–€15,000 | $20,000–$30,000 |
| NanoKnife (IRE) | €10,000–€18,000 | $25,000–$40,000 |
What’s typically included:
What’s NOT included:
On insurance: Most international patients self-pay. However, some US private insurers – particularly premium international health plans – do cover treatment at accredited German hospitals. It’s worth checking your policy before ruling it out. UK patients with private health insurance should also review their overseas treatment provisions.
A second opinion from a German tumour board isn’t just reassurance – it can fundamentally change your treatment plan. German oncologists frequently recommend a different approach from what was proposed locally: less aggressive, more targeted, or a therapy that simply wasn’t available to your original team.
What documents to prepare:
Most German hospitals accept digital files sent securely online – you don’t need to travel to get a second opinion.
What happens after the second opinion: You receive a written treatment recommendation covering diagnosis confirmation, staging, and a proposed treatment plan with options. You can then choose to proceed with treatment in Germany, or take the opinion back to your local oncologist. There’s no obligation either way.
CancerRounds connects you directly with vetted German oncologists for a prostate cancer second opinion – with an initial response within 4 hours, 100% confidential, and no obligation to proceed. You don’t need to navigate German hospital bureaucracy alone.
Non-EU patients (including those from the USA, UK, and Gulf countries) need a Schengen medical visa to travel to Germany for treatment. The process is straightforward when you have a hospital invitation letter:
CancerRounds handles the invitation letter and visa documentation as part of its coordination service.
All four cities have major international airports with direct connections from the USA, UK, and Gulf countries.
| Treatment | Typical Stay |
|---|---|
| Robotic prostatectomy (da Vinci) | 7–10 days |
| Radiation therapy (IMRT, full course) | 4–6 weeks |
| Proton therapy (full course) | 4–6 weeks |
| HIFU | 2–4 days |
| NanoKnife (IRE) | 3–5 days |
| Lutetium-177 PSMA (per cycle) | 3–5 days |
| Diagnostic workup / second opinion | 3–5 days |
All major German cancer centres have English-speaking medical staff and dedicated international patient coordinators. You will not face a language barrier at Martini-Klinik, Charité, LMU Munich, or Urologie Gronau.
Accommodation near major hospitals ranges from hospital-affiliated guesthouses to serviced apartments and hotels within walking distance. CancerRounds provides full travel coordination – from accommodation booking to airport transfers – so you can focus entirely on your health.
Getting prostate cancer treatment abroad involves more than booking a flight. You need the right hospital for your specific diagnosis, a specialist who has treated your exact cancer type at high volume, and someone who can coordinate the logistics so you can focus on getting well.
That’s what CancerRounds does.
Here’s what the service includes:
Share your medical reports and get a free evaluation from a German prostate cancer specialist within 4 hours.
Whether you’re seeking a second opinion on a recent diagnosis, looking for Lutetium-177 PSMA therapy, or exploring robotic surgery options, the first step is a free, no-obligation evaluation. You deserve the best possible care – and we’ll help you find it.
Germany is consistently ranked among the top two or three countries globally for prostate cancer care, alongside the USA and Japan. What distinguishes it is the combination of surgical volume (Martini-Klinik, Urologie Gronau), access to advanced therapies like Lutetium-177 PSMA and NanoKnife, and a structured multidisciplinary approach. For international patients, Germany also offers significantly lower costs than the USA with equivalent or superior clinical quality.
Costs vary by treatment type. Robotic prostatectomy runs €18,000–€20,000; IMRT radiation €12,000–€18,000; proton therapy €20,000–€35,000; Lutetium-177 PSMA therapy €15,000–€25,000 per cycle; HIFU €8,000–€15,000; NanoKnife €10,000–€18,000. These figures include the procedure, hospital stay, and core diagnostics. Travel and accommodation are additional.
Absolutely. Germany actively welcomes international patients. All major cancer centres have dedicated international patient departments that handle appointment scheduling, medical visa invitation letters, translation, and billing in foreign currencies. There are no restrictions on non-EU nationals receiving treatment as private patients.
Lutetium-177 PSMA therapy (Lu-177 PSMA-617, brand name Pluvicto) is a radioligand therapy for metastatic prostate cancer. It works by attaching a radioactive isotope to a molecule that binds to PSMA – a protein found in high concentrations on prostate cancer cells – and irradiating them from within. It was developed at DKFZ Heidelberg and is widely available at German nuclear medicine centres including LMU Munich, University Hospital Düsseldorf, and University Hospital Bonn. The VISION trial showed it reduced overall mortality by 38% in eligible patients.
Germany’s 5-year relative survival rate for prostate cancer is 92%, according to the German Cancer Registry. For localised disease (Stage 1–2), the 5-year survival rate exceeds 97% after surgery at high-volume centres. For advanced metastatic disease treated with innovative methods like Lutetium-177, 2-year survival rates reach approximately 60% – compared to around 25% with standard treatment alone.
It depends on the treatment. Robotic surgery requires 7–10 days in Germany. Radiation therapy (IMRT) runs 4–6 weeks. Lutetium-177 PSMA therapy involves 3–5 days per cycle, with multiple cycles spaced 6–8 weeks apart. HIFU and NanoKnife are typically 3–5 day stays. A diagnostic workup or second opinion can be completed in 3–5 days.
Yes. All major cancer centres – Martini-Klinik, Charité, LMU Munich, Urologie Gronau, and Vitus Private Clinic – have English-speaking medical staff and dedicated international patient coordinators. Many senior oncologists and surgeons trained or published internationally and are fully fluent in English. You will not face a language barrier at any of the hospitals recommended in this guide.
Both are minimally invasive focal therapies for localised prostate cancer, but they work differently. HIFU uses focused ultrasound waves to heat and destroy prostate tissue – no incisions, no radiation. NanoKnife (IRE) uses short electrical pulses to create pores in cancer cell membranes, causing cell death without thermal damage. NanoKnife is particularly advantageous for tumours near nerves and blood vessels, as it preserves these structures better than heat-based methods. HIFU is slightly more widely available; NanoKnife requires a highly specialised team.
Gather your biopsy report (with Gleason score), full PSA history, MRI/CT scans, and any existing treatment summaries. Submit these digitally – most German hospitals and coordination services accept secure digital uploads. CancerRounds connects you with a vetted German prostate cancer specialist within 4 hours of submission, 100% confidential, with no obligation to proceed to treatment.
You’ll need: (1) biopsy pathology report with Gleason score and grade group; (2) full PSA history with dates; (3) MRI and/or CT scans in digital format (DICOM files preferred); (4) PSMA PET-CT results if available; (5) any previous treatment summaries; (6) current medications list; (7) valid passport for visa application. Your German hospital or CancerRounds coordinator will provide a checklist specific to your case.
.webp){kind=logo}
Get expert guidance instantly
Tell us about your condition and we will help you find the right care.
Get expert guidance instantly
Share a few details and our medical team gets back to you within 4 hours with the next steps.
Tell us what you are facing and our medical team will guide you to the right doctors, hospitals and treatment.
Free Review, No Commitment
Free assessment with no pressure to proceed.
Trusted by 100,000+ Patients
Across 125+ countries worldwide
500+ Top Partner Hospitals
Globally accredited medical facilities
5000+ Expert Specialists
Senior doctors across major specialties.
Making quality healthcare accessible to patients worldwide
Everything you need to know about choosing the right hospital, doctor and treatment plan.